Effect of vitamin D supplementation in treatment of women with polycystic ovary syndrome
Phase 3
Completed
- Conditions
- Polycystic ovary syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT201604145623N75
- Lead Sponsor
- Vice chancellor for research, Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 90
Inclusion Criteria
Patients with PCOS according to Rotterdam criteria
Aged 18 to 40 years
Exclusion Criteria
Pregnant during the intervention
Androgen secreting tumors
Hyperprolactinemia
Thyroid dysfunction
Diabetes or impaired glucose tolerance
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total testosterone. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Sex hormone-binding globulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method Total antioxidant. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Hirsutism. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical observation.;Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms, including VDR activation, underlie vitamin D's anti-inflammatory and antioxidant effects in PCOS (E28.2) trials like IRCT201604145623N75?
How does vitamin D supplementation compare to standard-of-care treatments like metformin in reducing inflammation and oxidative stress in PCOS (E28.2) patients?
Which specific biomarkers of inflammation and oxidative stress, such as IL-6 or MDA, are used to assess vitamin D efficacy in IRCT201604145623N75?
What are the potential adverse events and management strategies for vitamin D supplementation in phase III PCOS (E28.2) trials?
Are there combination therapies involving vitamin D and inositols or other supplements for PCOS (E28.2) oxidative stress reduction?